Michael Minogue - Insulet Independent Director
| PODD Stock | USD 173.94 1.28 0.73% |
Director
Mr. Michael R. Minogue is an Independent Director of Insulet Corporationrationration. Mr. Minogue is the Chief Executive Officer, President and Chairman of Abiomed Inc., a global leader in healthcare technology and innovation. A seasoned business executive with more than two decades of experience, he joined Abiomed from GE Healthcare, where he holds three patents and spent 11 years developing expertise in sales, marketing, product development, information technologies and softwareservice operations. He currently serves on the Board of Directors of AdvaMed, is the Chairman of the Medical Device Innovation Consortium, and serves as the Chairman of the Governors Advisory Council on Veterans Services for the Commonwealth of Massachusetts. He is also on the Board of Managers for Bioventus LLC and recently stepped down from his position as Chairman after concluding ten years of service on the Board of Directors for MassMEDIC. Mr. Minogue is the CoFounder and Chairman of the Mentoring Veterans Program, a nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the life sciences industries. He served as an Infantry officer in the U.S. Army, which included multiple distinctions, including Airborne Ranger, Desert Storm Veteran and he was awarded the Bronze Star. Mr. Minogue received a BS, Engineering Management from the United States Military Academy at West Point and an MBA from the University of Chicago. Mr. Minogue brings distinguished senior executive leadership experience, as well as direct experience driving innovation and product development. since 2017.
| Age | 50 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 100 Nagog Park, Acton, MA, United States, 01720 |
| Phone | 978 600 7000 |
| Web | https://www.insulet.com |
Insulet Management Efficiency
The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3413 %, meaning that it created $0.3413 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.11. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Intangibles To Total Assets are forecasted to decline to 0.06.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Chidsey | Encompass Health Corp | 58 | |
| Barry Smith | The Ensign Group | 64 | |
| Richard LaRoche | National HealthCare | 74 | |
| Christopher Reidy | Encompass Health Corp | 64 | |
| Arthur Ellis | CryoCell International | N/A | |
| Ann Blouin | The Ensign Group | 65 | |
| John Maupin | Encompass Health Corp | 73 | |
| Bryan Cressey | Select Medical Holdings | 71 | |
| Antoinette Hubenette | The Ensign Group | 67 | |
| Daniel Thomas | Select Medical Holdings | 62 | |
| Russell Carson | Select Medical Holdings | 77 | |
| William Frist | Select Medical Holdings | 69 | |
| Yvonne Curl | Encompass Health Corp | 65 | |
| Edward Shaw | Encompass Health Corp | 73 | |
| James Dalton | Select Medical Holdings | 73 | |
| George Gaines | CryoCell International | 61 | |
| Donald Correll | Encompass Health Corp | 70 | |
| Leslye Katz | Encompass Health Corp | 66 | |
| Malene Davis | The Ensign Group | 55 | |
| Marilyn Tavenner | Select Medical Holdings | 69 | |
| Daren Shaw | The Ensign Group | 61 | |
Management Performance
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.0609 |
Insulet Leadership Team
Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Benjamin, Senior Vice President R&D, New Product Development and Commercialization | ||
| Sally Crawford, Lead Independent Director | ||
| Philip Hildale, Senior Care | ||
| John Fallon, Independent Director | ||
| Mark Field, Senior CTO | ||
| Laetitia Cousin, Quality Affairs | ||
| Deborah Gordon, Vice President Investor Relations and Corporate Communications | ||
| Daniel Levangie, Independent Director | ||
| James Mullen, Independent Director | ||
| John Kapples, Senior Vice President General Counsel, Secretary | ||
| Patrick Sullivan, CEO and President and Director | ||
| Wayde McMillan, CFO, Executive Vice President | ||
| Charles Liamos, Director of Advanced Technology and Director | ||
| Michael Levitz, CFO | ||
| Bradley Thomas, Executive VP of HR and Organizational Devel. | ||
| Charles Alpuche, Senior Vice President Global Manufacturing and Operations | ||
| David Lemoine, Independent Director | ||
| James Hollingshead, CEO President | ||
| Jessica Hopfield, Director | ||
| David Colleran, Vice President General Counsel | ||
| Brittany Bradrick, Vice President - Strategy and Corporate Development | ||
| Bret Christensen, Chief Commercial Officer | ||
| Deborah CPA, Vice Relations | ||
| Timothy Scannell, Director | ||
| Michael Minogue, Independent Director | ||
| Steven Sobieski, Independent Director | ||
| Aiman AbdelMalek, Senior Vice President Advanced Technology and Engineering | ||
| Corinne Nevinny, Independent Director | ||
| Regina Sommer, Independent Director | ||
| Mark Licari, Vice President - Global Manufacturing and Operations | ||
| Prem Singh, Senior Operations | ||
| Angela Wiczek, Senior Communications | ||
| Lauren Budden, Chief VP | ||
| Michael Spears, Senior Vice President Quality, Regulatory, and Clinical Affairs | ||
| Joseph Zakrzewski, Independent Director | ||
| Shacey Petrovic, Chief Commercial Officer | ||
| Trang Ly, Vice President and Medical Director |
Insulet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.0609 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 12.91 B | ||||
| Shares Outstanding | 70.02 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 99.69 % | ||||
| Number Of Shares Shorted | 3.12 M | ||||
| Price To Book | 16.75 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Insulet using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.Note that the Insulet information on this page should be used as a complementary analysis to other Insulet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Insulet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.043 | Earnings Share 2.94 | Revenue Per Share 24.331 | Quarterly Revenue Growth 0.379 | Return On Assets 0.0609 |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.